for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Abbott Laboratories

ABT.N

Latest Trade

81.62USD

Change

1.80(+2.26%)

Volume

229,343

Today's Range

80.70

 - 

81.86

52 Week Range

65.44

 - 

88.76

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Omada Health Says Co, Abbott To Integrate Abbott's Freestyle Libre System With Co's Digital Care Program

Oct 14 (Reuters) - Abbott Laboratories <ABT.N>::OMADA HEALTH SAYS CO, ABBOTT TO INTEGRATE ABBOTT'S FREESTYLE LIBRE SYSTEM WITH CO'S DIGITAL CARE PROGRAM.

Abbott Laboratories Says Late-Breaking Data Shows Mitraclip Increases Life Expectancy

Sept 29 (Reuters) - Abbott Laboratories <ABT.N>::LATE-BREAKING DATA SHOWS ABBOTT'S MITRACLIP™ IS COST EFFECTIVE, INCREASES LIFE EXPECTANCY AND IMPROVES QUALITY OF LIFE.

FDA Approves Abbott's "Low Dose," Recharge-Free Spinal Cord Stimulation System With Up To Ten Year Battery Life For People Living With Chronic Pain

Sept 26 (Reuters) - Abbott Laboratories <ABT.N>::FDA APPROVES ABBOTT'S "LOW DOSE," RECHARGE-FREE SPINAL CORD STIMULATION SYSTEM WITH UP TO TEN YEAR BATTERY LIFE* FOR PEOPLE LIVING WITH CHRONIC PAIN.ABBOTT LABORATORIES - PROCLAIM XR IS CURRENTLY UNDER REVIEW FOR CE MARK.

Abbott And Sanofi Partner To Integrate Glucose Sensing And Insulin Delivery Technologies

Sept 16 (Reuters) - Abbott Laboratories <ABT.N>::ABBOTT AND SANOFI PARTNER TO INTEGRATE GLUCOSE SENSING AND INSULIN DELIVERY TECHNOLOGIES TO HELP CHANGE THE WAY DIABETES IS MANAGED.ABBOTT LABORATORIES - ABBOTT AND SANOFI ARE PARTNERING TO INTEGRATE GLUCOSE SENSING AND INSULIN DELIVERY TECHNOLOGIES.

Abbott Sets Quarterly Dividend Of $0.32 Per Share

Sept 12 (Reuters) - Abbott Laboratories <ABT.N>::SETS QUARTERLY DIVIDEND OF $0.32PER SHARE.

Abbott CEO Says FreeStyle Libre Can Achieve $5 Bln In Sales "In A Reasonable Time"

July 17 (Reuters) - Abbott Laboratories <ABT.N>::ABBOTT LABORATORIES SAYS HAS RESEARCH AND DEVELOPMENT PROGRAMS UNDERWAY NOT ONLY FOR ENHANCEMENT AND EXPANSION OF FREESTYLE LIBRE, BUT ALSO IN CATEGORIES BEYOND DIABETES.ABBOTT LABORATORIES CEO SAYS FREESTYLE LIBRE CAN ACHIEVE $5 BILLION IN SALES "IN A REASONABLE TIME".

Abbott Laboratories Reports Q2 Gaap Earnings Per Share $0.56 From Continuing Operations

July 17 (Reuters) - Abbott Laboratories <ABT.N>::ABBOTT REPORTS SECOND-QUARTER 2019 RESULTS.Q2 ADJUSTED EARNINGS PER SHARE $0.82 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.Q2 GAAP EARNINGS PER SHARE $0.56 FROM CONTINUING OPERATIONS.Q2 EARNINGS PER SHARE ESTIMATE $0.80 -- REFINITIV IBES DATA.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $3.21 TO $3.27 FROM CONTINUING OPERATIONS.SEES Q3 ADJUSTED EARNINGS PER SHARE $0.83 TO $0.85 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.SEES Q3 2019 GAAP EARNINGS PER SHARE $0.53 TO $0.55 FROM CONTINUING OPERATIONS.SEES FY 2019 GAAP EARNINGS PER SHARE $2.06 TO $2.12 FROM CONTINUING OPERATIONS.RAISING FULL-YEAR GUIDANCE FOR ORGANIC SALES GROWTH TO 7 TO 8 PERCENT.FY2019 EARNINGS PER SHARE VIEW $3.22 -- REFINITIV IBES DATA.Q3 EARNINGS PER SHARE VIEW $0.85 -- REFINITIV IBES DATA.QTRLY SALES OF $ 7,979 MILLION VERSUS $ 7,767 MILLION REPORTED LAST YEAR.RAISING FULL-YEAR EPS FORECAST.FORECASTS SPECIFIED ITEMS FOR Q3 2019 OF $0.30 PER SHARE.FORECASTS NET SPECIFIED ITEMS FOR FULL YEAR 2019 OF $1.15 PER SHARE..QTRLY PEDIATRIC SALES $1,051 MILLION, UP 0.1% ON A REPORTED BASIS.FY2019 REVENUE VIEW $31.99 BILLION -- REFINITIV IBES DATA.SAYS "OUR SALES GROWTH ACCELERATED AND IS SUSTAINABLE".QTRLY TOTAL NUTRITION SALES $1,875 MILLION, UP 0.9% ON REPORTED BASIS.QTRLY TOTAL DIAGNOSTICS SALES $1,905 MILLION, UP 1.7% ON REPORTED BASIS.Q2 REVENUE VIEW $8.00 BILLION -- REFINITIV IBES DATA.SECOND-QUARTER WORLDWIDE SALES INCREASED 7.5 PERCENT ON AN ORGANIC BASIS.

Abbott Receives U.S. Approval Of Next-Generation Mitraclip

July 15 (Reuters) - Abbott Laboratories <ABT.N>::ABBOTT RECEIVES U.S. APPROVAL OF NEXT-GENERATION MITRACLIP®, BRINGING NEW ENHANCEMENTS TO ABBOTT'S LEADING MITRACLIP PLATFORM.ABBOTT LABORATORIES - CO HAS RECEIVED U.S. FDA APPROVAL FOR MOST ADVANCED MITRACLIP HEART VALVE REPAIR DEVICE TO TREAT MITRAL REGURGITATION.

Abbott Announces FDA Approval Of Alinity s System

July 11 (Reuters) - Abbott Laboratories <ABT.N>::ABBOTT ANNOUNCES FDA APPROVAL OF THE ALINITY™ S SYSTEM, THE LATEST TECHNOLOGY FOR SCREENING AND PROTECTING THE U.S. BLOOD AND PLASMA SUPPLY.ABBOTT LABORATORIES - ALINITY™ S SYSTEM WILL SCREEN U.S. BLOOD AND PLASMA SUPPLY FASTER AND MORE EFFICIENTLY WHILE MAINTAINING HIGHEST LEVELS OF ACCURACY.

Enzo Biochem Says CO Considering All Available Options For Challenging Federal Circuit Panel's Decision

June 21 (Reuters) - Abbott Laboratories <ABT.N>::ENZO BIOCHEM - U.S. COURT OF APPEALS ISSUED OPINION AFFIRMING LOWER COURT JUDGMENTS OF PATENT INVALIDITY FOR U.S. PATENT NOS. 6,992,180 & 8,097,405.ENZO BIOCHEM INC - COMPANY IS CONSIDERING ALL AVAILABLE OPTIONS FOR CHALLENGING FEDERAL CIRCUIT PANEL'S DECISION.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up